Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 11/20 | 0.49 |
| ▸ | CCNK | O75909 | 11/20 | 0.49 |
| ▸ | CDK9 | P50750 | 11/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.49 |
| ▸ | CDK2 | P24941 | 9/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 7/20 | 0.36 |
| ▸ | CCNH | P51946 | 7/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363980 | 1.00 | CCNT1 (0.49) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25029249 | 0.88 | GSK3B (0.45) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29362063 | 0.88 | GSK3B (0.45) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29364077 | 0.87 | GSK3B (0.45) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25028677 | 0.87 | GSK3B (0.45) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25029275 | 0.87 | CCNT1 (0.47) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29363798 | 0.87 | CCNT1 (0.47) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29363918 | 0.85 | CCNK (0.43) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25029061 | 0.85 | CCNK (0.43) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25027656 | 0.84 | GSK3B (0.43) | CCNT1CCNKCDK9CDK12CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-115996926-A | Indole compounds as androgen receptor modulators | 尼多生物科学有限公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCNT1 2902/4885CCNK 2842/4885CDK9 801/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | CCNT1 2934/4885CCNK 2738/4885CDK9 740/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | CCNT1 3119/4885CCNK 3289/4885CDK9 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.